Clinical research of insulin glargine U300 basal‐bolus therapy and insulin degludec/aspart co‐formulation in type 2 diabetes mellitus: A real world experience
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Clinical Practice"
DOI: 10.1111/ijcp.14377
Abstract: Insulin degludec/aspart (IDegAsp) and insulin glargine U300 (IGlarU300) have recently emerged as popular new‐generation insulin analogues. The aim of this real‐life study was to investigate the patient profiles in which IGlarU300 and IDegAsp were preferred… read more here.
Keywords: insulin; degludec aspart; insulin glargine; glargine u300 ... See more keywords
A Low Fasting Glucose/Estimated Average Glucose Ratio was Associated with Superior Response to Insulin Degludec/Aspart Compared to Basal Insulin in Patients with Type 2 Diabetes.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of diabetes investigation"
DOI: 10.1111/jdi.13634
Abstract: INTRODUCTION Benefits of once-daily insulin degludec/aspart (IDegAsp) compared to basal insulin in type 2 diabetes has not been established. MATERIALS AND METHODS This is a retrospective observational study. From a basal insulin cohort from 3… read more here.
Keywords: insulin; degludec aspart; control; compared basal ... See more keywords